ICAgen Signs $75 Million Drug-Development Deal With Bristol-Myers

Dec 21, 1998

Premium

RESEARCH TRIANGLE PARK, NC--ICAgen here has signed a two-year collaborative agreement with Bristol-Myers Squibb that could be worth as much as $75 million. The deal focuses on the development of small-molecule drugs to treat atrial fibrillation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Re-Think on Science Standards

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Faster Efforts

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

Graves Wins Top Australian Science Prize

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

This Week in Cell

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.

Main menu